Search Results for "diagnosis"

Standard response letter on hepatic effects observed with the use of givosiran.

This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.

Standard response letter on givosiran and use in patients with pre-existing kidney impairment from the ENVISION study.

Standard response letter on givosiran and the 36-month results of the ENVISION study, a phase 3 study evaluating the efficacy and safety of givosiran in patients with a documented diagnosis of AHP.

Standard response letter on the monthly dosing administration and dosing window of givosiran in the ENVISION study.

Standard response letter on use of vutrisiran across baseline heart failure disease severity of patients enrolled in HELIOS-B.

External title: Patisiran RWE in hATTR Amyloidosis External description: This slide deck highlights real-world evidence (RWE) data on the use of patisiran in patients with hATTR amyloidosis, including patients with polyneuropathy, cardiomyopathy, solid organ transplant, concomitant treatment or treatment switch.

Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.

Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Standard response letter on renal effects observed with the use of givosiran.

Standard response letter on givosiran and hypersensitivity, including anaphylactic reactions, observed.

This infographic about AHP describes the types of the disease, including AIP, pathophysiology, clinical presentation of acute and chronic symptoms, epidemiology, and diagnosis

Standard response letter on CYP enzyme drug-drug interactions with givosiran.

Standard response letter on givosiran and injection site reactions during the phase 1, phase 1/2 open-label extension, and phase 3 ENVISION studies.

Standard response letter on lumasiran phase 3 clinical study ILLUMINATE-C, a study evaluating the efficacy and safety of lumasiran in infants to adult patients with PH1 and advanced kidney disease.

Standard response letter on the APOLLO-B OLE study of patisiran.

Standard response letter on patisiran and cardiac results in the Global OLE study, a study evaluating the long-term efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.

This infographic details the lumasiran clinical program (including ILLUMINATE) which investigates the treatment of primary hyperoxaluria type 1 with lumasiran.

Standard response letter on zilebesiran and the phase 2 studies: KARDIA-1, KARDIA-2, and KARDIA-3.

Standard response letter on givosiran and elevations in blood homocysteine.

Standard response letter on givosiran and its use in pregnant or lactating patients.

Standard response letter on patisiran and the APOLLO-B study, a study evaluating the efficacy and safety of patisiran in patients with ATTR with cardiomyopathy, including both hATTR and wtATTR.

Standard response letter on vutrisiran and the HELIOS-B study, a phase 3 study evaluating the efficacy and safety of vutrisiran in patients with the cardiomyopathy of ATTR, including both hATTR and wtATTR.

Standard response letter on patisiran and use in patients with heart transplant.